So, here's what happened to PepGen Inc. (PEPG) on Tuesday: the stock took a nosedive. The reason? Some early, and frankly underwhelming, data from a clinical trial. The company announced topline results from the lowest dose group in its ongoing Phase 2 trial for a drug called PGN-EDODM1, which is being tested for myotonic dystrophy type 1 (DM1). Investors didn't like what they saw, and the shares were down over 44% in premarket trading.
Let's break down the numbers, because they tell a story of disappointment with a significant asterisk. In the group of patients receiving a 5 mg/kg dose, the drug achieved a mean splicing correction of 7.3%. For context, splicing correction is a key biological measure for this disease, and the placebo group showed a 6.8% correction. So, the drug's effect was... minimal at this dose. This was a letdown compared to earlier, non-trial data that had suggested corrections of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg.
The Outlier in the Room
Now, here's where it gets interesting. That disappointing 7.3% average? It was dragged way down by one single patient. This outlier actually got worse, showing a 70.8% *worsening* in splicing correction. If you take that one person out of the equation, the math changes dramatically. The mean splicing correction for the remaining treated patients jumps to 22.9%. That's a much more encouraging signal hiding in what looks like a failed experiment. It's a classic case of how one weird data point can skew the whole story.
Mixed Signals on Function
Beyond the splicing numbers, the trial looked at whether patients actually felt or functioned better. The results here were a mixed bag. One test for hand muscle stiffness, called video Hand Opening Time (vHOT), showed a positive trend of improvement in the drug group versus a worsening in the placebo group, though both returned to baseline by week 16. However, other functional tests—like a 10-meter walk/run and handgrip strength—didn't show any meaningful improvements at this starting dose.
The company also noted that muscle tissue concentrations of the drug were measurable in most patients, which is a good sign that it's getting where it needs to go. On the business side, PepGen says it has enough cash to keep the lights on into the second half of 2027, which gives it some runway to figure this out.
The Bigger Picture: Higher Doses and Regulatory Hurdles
This low-dose data is just one piece of the puzzle, and arguably not the most important one. The real question for investors is what happens at higher doses. PepGen is already dosing patients at 10 mg/kg and expects to report that data in the second half of 2026. More importantly, remember that data from September 2025? That came from a 15 mg/kg dose group in a different study, and it showed a mean splicing correction of 53.7%. That's a massive, promising result. It suggests this drug might need a certain potency to really work, making the low-dose data less predictive of ultimate success or failure.
There's another cloud hanging over the stock, too. Back in March, the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on this very Phase 2 trial. The agency had questions about the company's preclinical pharmacology and toxicology studies. That hold hasn't been lifted, and it's a regulatory overhang that adds risk and uncertainty for investors.
So, where does that leave us? A bad headline number sent the stock crashing, but the details reveal a more nuanced picture. One patient ruined the average, higher doses have historically worked much better, and the company has time and money to keep testing. For biotech investors, Tuesday's plunge is a harsh reminder that early clinical data is a volatile, messy business, and sometimes you have to look past the averages to see what's really going on.
